Company: Eli Lilly
Posted by LillyRep_Zepbound_7745 · March 19, 2026
Tags: field, strategy, launch
efficacy gap still exists and it matters for the severe patients.
NVO will lead with "new dose" everywhere — fine.
tirzepatide story hasnt changed oral semaglutide is the thing I'm actually watching.
pill with broad formulary coverage is a different fight.
12 upvotes · 5 comments